Percutaneous endoscopic gastrostomy in the patient with amyotrophic lateral sclerosis: Risk vs benefit?

Practical Gastroenterology

Volumn 32, Issue 3, 2008, Pages 24-34

  Procaccini, Nicholas J ^a   Nemergut, Edward C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCUSATE SODIUM; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE;

AMYOTROPHIC LATERAL SCLEROSIS; ASPIRATION PNEUMONIA; BODY POSTURE; CLINICAL DECISION MAKING; CONSTIPATION; DIETARY INTAKE; DIETITIAN; DYSPHAGIA; FORCED EXPIRATORY VOLUME; HUMAN; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; NASOGASTRIC TUBE; NUTRITIONAL ASSESSMENT; NUTRITIONAL HEALTH; NUTRITIONAL SUPPORT; PATIENT COUNSELING; PATIENT MONITORING; PATIENT POSITIONING; PATIENT SELECTION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SWALLOWING;

EID: 42149094403     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet, 2007;369:2031-2041.
2. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev, 2007;24;(1): CD001447.
3. Desport JC, Preux PM, Magy, L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr, 2001; 74: 328-334.
4. Mazzini L, Corra T, Zaccala M, et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol, 1995; 242: 695-698.
5. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population based study. Neurology, 2002; 59:99-103.
6. Park RHR, Allison MC, Lang J, et al. Randomised comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with persisting neurologic dysphagia. Br Med J, 1992; 304:1406-1409.
7. Chio A, Finnocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous gastrostomy in ALS. ALS percutaneous endoscopic gastrostomy study group. Neurology, 1999; 53:1123-1125.
8. Miller RG, Rosenberg JA, Gelinas DF. Practice Parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology, 1999; 52:1311-1323.
9. Moser B, Lirk P, Lechner M, et al. General anesthesia in a patient with motor neuron disease. Eur J Anaesthesiol, 2004; 21(11):921-923.
10. Baur CP, Schara U, Schlecht R, et al. Anaesthesia in neuromuscular disorders. Part 2: specific disorders. Anasthesiol Intensivmed Notfallmed Schmerzther, 2002; 37: 125-137.
11. Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology, 2002; 58:485-487.
12. Chiò A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry, 2004;74:645-647.
13. Mannino M, Cellura E, Grimaldi G, et al. Telephone follow-up for patients with amyotrophic lateral sclerosis. Eur J Neurol, 2007; 14:79-84.
14. Toepfer M, Folwaczny C, Klauser A, et al. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. ALS and other Motor Neuron Disorders, 1999;1:15-19.
15. Toepfer M, Schroeder M, Klauser A., et al. Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radioopaque markers. Eur J Med Res, 1997;2:473-476.
16. Johanson JF, Morton D, Geenan J, et al. Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride Channel Activator, in Patients With Chronic Constipation. Am J Gastro, 2007; 102:1-8.